Literature DB >> 15086328

Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency.

L A Valentino1, N Hakobyan, T Kazarian, K J Jabbar, A A Jabbar.   

Abstract

Haemophilia is a genetic disease as a result of the deficiency of blood coagulation factor VIII or IX. Bleeding is common, especially into joints where an inflammatory, proliferative synovitis develops resulting in a debilitating arthritis, haemophilic arthropathy. The pathogenesis of blood-induced haemophilic synovitis (HS) is poorly understood. The gross, microscopic and ultrastructural changes that occur in the synovial membrane following human and experimental hemarthrosis have been described. Repeated episodes of bleeding induce synoviocyte hypertrophy and hyperplasia, an intense neovascular response and inflammation of the synovial membrane. The component(s) in blood that initiates these changes is(are) not known, although iron is often proposed as one possibility. Here, we describe a novel murine model of human haemophilia A, which facilitates the examination of large number of animals and tissue specimens. The effects of hemarthrosis on the physical, gross and microscopic changes evoked following joint bleeding are described. Controlled, blunt trauma to the knee joint consistently resulted in joint swelling because of a combination of bleeding and inflammation. Hemosiderin was found in the synovial membrane. Similar to hemarthrosis in human haemophilia, joint bleeding resulted in acute morbidity evidenced by inactivity, weight loss and immobility. With time the animals recovered. The model of experimental murine HS described here has utility in the study of the pathogenesis of HS. This is the first of a series of articles, which will discuss the pathophysiology and characterize the model, with comparison of his model to others which have been published previously. It should provide a useful model to test potential therapeutic interventions.

Entities:  

Mesh:

Year:  2004        PMID: 15086328     DOI: 10.1111/j.1365-2516.2004.00899.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  20 in total

1.  Activation state of platelets in experimental severe hemophilia A.

Authors:  Maud Teyssandier; Sandrine Delignat; Julie Rayes; Marijke Bryckaert; Martine Jandrot-Perrus; Srini V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

2.  A microfluidic model of hemostasis sensitive to platelet function and coagulation.

Authors:  R M Schoeman; K Rana; N Danes; M Lehmann; J A Di Paola; A L Fogelson; K Leiderman; K B Neeves
Journal:  Cell Mol Bioeng       Date:  2016-10-24       Impact factor: 2.321

3.  Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice.

Authors:  Esther J Cooke; Jenny Y Zhou; Tine Wyseure; Shweta Joshi; Vikas Bhat; Donald L Durden; Laurent O Mosnier; Annette von Drygalski
Journal:  Thromb Haemost       Date:  2018-05-30       Impact factor: 5.249

4.  The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy.

Authors:  Hillary J Braun; Hyeon Joo Kim; Constance R Chu; Jason L Dragoo
Journal:  Am J Sports Med       Date:  2014-03-14       Impact factor: 6.202

Review 5.  Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia BWFH State-of-the-Art Session on Therapeutic Gene Transfer Buenos Aires, Argentina.

Authors:  R R Montgomery; P E Monahan; M C Ozelo
Journal:  Haemophilia       Date:  2010-07       Impact factor: 4.287

Review 6.  Animal models of hemophilia.

Authors:  Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

7.  Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

Authors:  Atsushi Muto; Kazutaka Yoshihashi; Minako Takeda; Takehisa Kitazawa; Tetsuhiro Soeda; Tomoyuki Igawa; Zenjiro Sampei; Taichi Kuramochi; Akihisa Sakamoto; Kenta Haraya; Kenji Adachi; Yoshiki Kawabe; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Blood       Date:  2014-10-01       Impact factor: 22.113

Review 8.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

9.  Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A.

Authors:  C D Porada; C Sanada; C R Long; J A Wood; J Desai; N Frederick; L Millsap; C Bormann; S L Menges; C Hanna; G Flores-Foxworth; T Shin; M E Westhusin; W Liu; H Glimp; E D Zanjani; J N Lozier; V Pliska; G Stranzinger; H Joerg; D C Kraemer; G Almeida-Porada
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

Review 10.  Orthopedic disorders of the knee in hemophilia: A current concept review.

Authors:  E Carlos Rodriguez-Merchan; Leonard A Valentino
Journal:  World J Orthop       Date:  2016-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.